治疗中血小板反应性可预测接受经皮血管成形术的外周动脉疾病患者的不良事件
该前瞻性单中心观察性研究纳入177例外周动脉疾病行经皮腔内血管成形术并接受双联抗血小板治疗的患者,用光透射聚集法检测血小板功能。花生四烯酸诱导的高治疗中血小板反应性与二磷酸腺苷诱导的高治疗中血小板反应性分别为45%和32%,二者均为死亡的独立预测因素,而二磷酸腺苷诱导的低血小板反应性与出血风险升高独立相关。
要点
- 花生四烯酸诱导的高治疗中血小板反应性为死亡的独立预测因素(HR 3.8)。
- 二磷酸腺苷诱导的高治疗中血小板反应性为死亡的独立预测因素(HR 4.8)。
- 二磷酸腺苷诱导的光透射聚集法≤41%与出血独立相关(HR 14.6)。
核心结论
- 本研究发现氯吡格雷和阿司匹林高血小板反应性患病率较高,且与死亡风险显著相关。
- 相反,氯吡格雷低血小板反应性与出血风险升高相关。
- 这些结果说明血小板抑制程度与外周动脉疾病患者的血栓和出血并发症均相关。
研究设计与样本
- 观察性、前瞻性、单中心研究,连续纳入177例外周动脉疾病接受经皮腔内血管成形术的患者。
- 患者接受阿司匹林联合一种P2Y12抑制剂的双联抗血小板治疗。
- 于经皮腔内血管成形术后24小时内采血,用光透射聚集法以花生四烯酸和二磷酸腺苷为激动剂评估血小板功能。
- 高治疗中血小板反应性定义为花生四烯酸诱导的光透射聚集法≥20%,或二磷酸腺苷诱导的光透射聚集法≥70%。
- 随访记录死亡、大截肢、靶血管再干预、急性心肌梗死和/或心肌血运重建、卒中/短暂性脑缺血发作及出血。
主要发现
- 花生四烯酸诱导的高治疗中血小板反应性和二磷酸腺苷诱导的高治疗中血小板反应性分别见于45%和32%的患者。
- 中位随访23个月期间记录到23例死亡(13%),27例(17.5%)接受靶肢体血运重建,2例(1.3%)截肢,6例(3.9%)心肌血运重建。
- 24例(15.6%)发生轻微出血。
- 出血并发症患者中二磷酸腺苷诱导的光透射聚集法中位值显著低于无出血患者(26.5%,22-39.2 vs 62%,44.5-74,p < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Few data are available on the association between a different entity of platelet inhibition on antiplatelet treatment and clinical outcomes in patients with peripheral artery disease (PAD). The aim of this study was to evaluate the degree of on-treatment platelet reactivity, and its association with ischaemic and haemorrhagic adverse events at follow up in PAD patients undergoing percutaneous transluminal angioplasty (PTA). METHODS: In this observational, prospective, single centre study, 177 consecutive patients with PAD undergoing PTA were enrolled, and treated with dual antiplatelet therapy with aspirin and a P2Y12 inhibitor. Platelet function was assessed on blood samples obtained within 24 h from PTA by light transmission aggregometry (LTA) using arachidonic acid (AA) and adenosine diphosphate (ADP) as agonists of platelet aggregation. High on-treatment platelet reactivity (HPR) was defined by LTA ≥ 20% if induced by AA, and LTA ≥ 70% if induced by ADP. Follow up was performed to record outcomes (death, major amputation, target vessel re-intervention, acute myocardial infarction and/or myocardial revascularisation, stroke/TIA, and bleeding). RESULTS: HPR by AA and HPR by ADP were found in 45% and 32% of patients, respectively. During follow up (median duration 23 months) 23 deaths (13%) were recorded; 27 patients (17.5%) underwent target limb revascularisation (TLR), two (1.3%) amputation, and six (3.9%) myocardial revascularisation. Twenty-four patients (15.6%) experienced minor bleeding. On multivariable analysis, HPR by AA and HPR by ADP were independent predictors of death [HR 3.8 (1.2-11.7), p = .023 and HR 4.8 (1.6-14.5), p = .006, respectively]. The median value of LTA by ADP was significantly lower in patients with bleeding complications than in those without [26.5% (22-39.2) vs. 62% (44.5-74), p < .001). LTA by ADP ≤ 41% was independently associated with bleeding HR 14.6 (2.6-24.0), p = .001] on multivariable analysis. CONCLUSIONS: In this study a high prevalence of on-clopidogrel and aspirin high platelet reactivity was found, which was significantly associated with the risk of death. Conversely, a low on-clopidogrel platelet reactivity was associated with a higher risk of bleeding. These results document that the entity of platelet inhibition is associated with both thrombotic and bleeding complications in PAD patients.
引用
- Grifoni E, Gori AM, Giusti B, et al. On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty. Eur J Vasc Endovasc Surg. 2018. PMID: 30025662. doi:10.1016/j.ejvs.2018.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。